Anti‐CD52 mAb maintenance therapy vs observation
Grades 3 and 4 adverse events ‐ not reported · people with chronic lymphocytic leukaemia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found